58986-61-1

Basic information

• Product Name: 3-(CYCLOPROPYLMETHOXY)BENZALDEHYDE
• Synonyms: 3-(CYCLOPROPYLMETHOXY)BENZALDEHYDE
• CAS NO: 58986-61-1
• Molecular Formula: C₁₁H₁₂O₂
• Molecular Weight: 176.21
• Mol File: 58986-61-1.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(CYCLOPROPYLMETHOXY)BENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(CYCLOPROPYLMETHOXY)BENZALDEHYDE(58986-61-1)
• EPA Substance Registry System: 3-(CYCLOPROPYLMETHOXY)BENZALDEHYDE(58986-61-1)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 58986-61-1(Hazardous Substances Data)

Upstream product

• 100-83-4 meta-hydroxybenzaldehyde 
• 7051-34-5 cyclopropylcarbinyl bromide 
• 5911-08-0 chloro(cyclopropyl)methane 

Downstream Products

• 58986-63-3 3-Cyclopropylmethoxynitrostyrol 
• 1459215-80-5 (L,Z)-2-[5-{3-(cyclopropylmethoxy)benzylidene}-4-oxo-2-thioxo-thiazolidin-3-yl]-3-phenyl-propionic acid 
• 1369703-60-5 (S)-N-(1-(3-(cyclopropylmethoxy)phenyl)ethyl)-3-((2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methoxy)propane-1-sulfonamide 
• 1198221-39-4 (R)-N-(1-(3-(cyclopropylmethoxy)phenyl)ethyl)-3-((2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methoxy)propane-1-sulfonamide 
• 1369704-88-0 C₂₂H₂₄F₃NO₃ 
• 1369704-85-7 C₂₂H₂₄F₃NO₃ 
• 1369703-51-4 (S)-N-(1-(3-(cyclopropylmethoxy)Phenyl)ethyl)-3-(methoxymethoxy)propane-1-sulfonamide 
• 1198224-26-8 (R)-N-(1-(3-(cyclopropylmethoxy)Phenyl)ethyl)-3-(methoxymethoxy)propane-1-sulfonamide 
• 1369704-79-9 (S)-N-(1-(3-(cyclopropylmethoxy)phenyl)ethyl)-3-hydroxypropane-1-sulfonamide 
• 1369704-76-6 (R)-N-(1-(3-(cyclopropylmethoxy)phenyl)ethyl)-3-hydroxypropane-1-sulfonamide 
• 1369704-64-2 (S)-3-(N-(1-(3-(cyclopropylmethoxy)phenyl)ethyl)sulfamoyl)propyl acetate 
• 1369704-61-9 (R)-3-(N-(1-(3-(cyclopropylmethoxy)phenyl)ethyl)sulfamoyl)propyl acetate 
• 1369704-49-3 (S)-3-chloro-N-(1-(3-(cyclopropylmethoxy)phenyl)ethyl)propane-1-sulfonamide 
• 1369704-46-0 (R)-3-chloro-N-(1-(3-(cyclopropylmethoxy)phenyl)ethyl)propane-1-sulfonamide 

Relevant articles and documents

Design and optimisation of a small-molecule TLR2/4 antagonist for anti-tumour therapy

In anti-tumour therapy, the toll-like receptor 2/4 (TLR2/4) signalling pathway has been a double-edged sword. TLR2/4 agonists are commonly considered adjuvants for immune stimulation, whereas TLR2/4 antagonists demonstrate more feasibility for anti-tumour therapy under specific chronic inflammatory situations. In individuals with cancer retaliatory proliferation and metastasis after surgery, blocking the TLR2/4 signalling pathway may produce favourable prognosis for patients. Therefore, here, we developed a small-molecule co-inhibitor that targets the TLR2/4 signalling pathway. After high-throughput screening of a compound library containing 14 400 small molecules, followed by hit-to-lead structural optimisation, we finally obtained the compound TX-33, which has effective inhibitory properties against the TLR2/4 signalling pathways. This compound was found to significantly inhibit multiple pro-inflammatory cytokines released by RAW264.7 cells. This was followed by TX-33 demonstrating promising efficacy in subsequent anti-tumour experiments. The current results provide a novel understanding of the role of TLR2/4 in cancer and a novel strategy for anti-tumour therapy.

ANTI-TUMOR EFFECT POTENTIATOR

There is provided an agent for potentiating the effects of an anti-tumor agent. An anti-tumor effect potentiator containing, as an active ingredient, a uracil compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein X represents a C1-5 alkylene group and one of methylene groups constituting the alkylene group is optionally substituted with an oxygen atom; R1 represents a hydrogen atom or a C1-6 alkyl group; R2 represents a hydrogen atom or a halogen atom; and R3 represents a C1-6 alkyl group, a C2-6 alkenyl group, a C3-6 cycloalkyl group, a (C3-6 cycloalkyl) C1-6 alkyl group, a halogeno-C1-6 alkyl group or a saturated heterocyclic group.

ALKOXY COMPOUNDS FOR DISEASE TREATMENT

The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.